ORIGINAL ARTICLE

CODEN: AAJMBG

# Nephrolithiasis induced end stage renal disease in patients on hemodialysis in Baghdad (A Multicenter study)

# Ali J. Hashim Al Saedi<sup>1\*</sup>, Abdul Hakeem A. Karim<sup>2</sup> and Mortadha Mohammad Hadi<sup>3</sup>

<sup>1</sup>Department of Medicine, College of Medicine Baghdad, University of Baghdad, Medical City, Baghdad, Iraq, <sup>2</sup>Department of Science, College of Basic Education, Al Mustansiryah University, Baghdad, Iraq and <sup>3</sup>Physician Department of Medicine Baghdad Teaching Hospital, Baghdad, Iraq

Abstract: Background: Kidney stones are the third most common disease of the urinary system. Nephrolithiasis still remains underappreciated cause of end stage renal disease. Clinical presentation varies from asymptomatic small stones to large obstructing staghorn calculi leading to chronic kidney disease. Objective: The study aims to evaluate prevalence of nephrolithiasis induced end stage renal disease among patients on maintenance Hemodialysis therapy. Patients and Methods: An analytic cross sectional multicenter study that involved 996 patients on maintenance Hemodialysis that was performed from August 2014 to February 2015 in the dialysis units in Baghdad. The patients were grouped into 49 patients who had nephrolithiasis and 947 as a control group, 29 were females and 20 were males. The age ranged between (38-71) years. All patients with nephrolithiasis were evaluated using abdominal ultrasonography and abdominal computed tomographyscan. Results: Total number of nephrolithiasis incident ESRD cases was 4.91 % (49 of 996 patients). The mean age of the patients with nephrolithiasis induced ESRD was  $56.41 \pm 8.26$  years, 28 patients (57.14%) distributed between ages 40 to 59 years old, 19 patients (38.77%) within age 60 years old and more, while only 2 patients (4.08%) seen between ages 20 to 39 years old and no patients reported below age of 20 years. Conclusion: Nephrolithiasis remains the cause of potentially avoidable end stage renal disease in too many patients despite recent major advances in the diagnosis and management of patients forming stones. Keywords: Nephrolithiasis, End stage renal disease, Hemodialysis.

# Introduction

Kidney stones are common, the life time incidence has increased to nearly 10% in the United States [1] and they are the third most common disease of the urinary system [2-3]. It is an increasingly prevalent systemic disorder with substantial health and economic consequences [4]. An initial kidney stone was most commonly seen in patients in their 30s and 40s; however, epidemiologic data now suggest that there has been an increase in nephrolithiasis in younger patients, which may coincide with the increase in metabolic syndrome such as diabetes. hypertension, and obesity in younger people [5-6].

Risk factors for stone formation include crystaliuria, socioeconomic factors, hot climate, family history and medications (e.g triametrine and calcium containing antacids) [7]. Kidney stones may be associated with complications such as infection, acute renal failure (due to obstructive uropathy), and chronic kidney disease [3]. The contribution of nephrolithiasis related to end stage renal disease (ESRD) in patients requiring renal replacement therapy (RRT) has never been specifically evaluated [8].

Nephrolithiasisstill remains underappreciated cause of ESRD and this is all the most unfortunate since such prognosis is now preventable in most cases [8]. There are four main types of kidney stones Calcium salts, uric acid, cysteine, and struvite are the constituents of most kidney stones [9]. Calcium oxalate and calcium phosphate stones make up 75-85% of the total and those constituents may be admixed in the same stone [1]. Risk factors for calcium stones are primary hyperparathyroidism, hypercalciuria, hyperoxaluria, and hypocitraturia [10]. Uric acid stones constitute 5-1% of all kidney stones and may be due gout, dehydration or metabolic syndrome [11]. Cysteine stones

constitute 1% and usually hereditary [12]. Lastly struvite stones which constitute 5-10 % of all kidney stones andcaused by infections with urease-splitting organisms such as *Proteus* and *Klebsiella* species that hydrolyze urea to ammonium, which alkalinizes the urine and leads to precipitation of phosphate ion complexes [2].

Aim of study: The aim of the study is:

- 1. Evaluating prevalence of nephrolithiasis induced ESRD among patients who develop ESRD from any other cause who are on maintenance dialysis therapy.
- 2. Evaluating the prevalence of nephrolithiasis induced ESRD among age groups and evaluating whether age is a risk factor for nephrolithiasis induced ESRD compared with patients who had ESRD from other causes.
- 3. Evaluating the prevalence of nephrolithiasis induced ESRD according to gender and evaluating whether gender is a risk factor for nephrolithiasis induced ESRD compared with patients who had ESRD from other causes.

# Material and Methods

An analytic cross sectional study performed in the period between August 2014 and February 2015 in the dialysis units in Baghdad hospitals (multicenter study) which include:

- 1. Baghdad teaching hospital.
- 2. AL Imamain AL\_Kadhimain teaching hospital.
- 3. AL\_kindy teaching hospital.
- 4. AL\_Karama teaching hospital.
- 5. AL\_Imam Ali general hospital.
- 6. Kidney transplant center/ Medical city.

Two groups were involved in the study, the study group and control group. The study group (49 patients) are the patients who have urinary stone disease as exclusive orpreponderant cause of ESRD who start maintenance dialysis therapy and they were assessed by means of detailed history including presenting clinical features at time of diagnosis (most common clinical presentations of the 49 patients who had nephrolithiasis induced ESRD were loin pain most commonly bilateral, anuria, hematuria and irritable symptoms of frequency and urgency). Also the history focused on the ways of confirming diagnosis and all the patients were evaluated using general urine examination (GUE), abdominal ultrasonography

and abdominal CT scan. The control group (947 patients) are those who have ESRD from causes other than nephrolithiasis and start maintenance dialysis therapy in the hospitals involved in this study. Data collection was focused on detecting patients start maintenance dialysis therapy because of nephrolithiasis as exclusive or preponderant cause of ESRD depending on the history of clinical presentation first and the investigations that performed at time of presentation to confirm the diagnosis and recording the age and gender of all patients independent on the cause of their ESRD. The analysis of these data had been done and the results were concluded and tabulated in tables and figures, to be compared with the results of other studies. All patients were informed on research purposes, and all patients records data is kept completely confidential.

Patients who developed renal stones after starting maintenance dialysis therapy are not involved in this study as well as there are three patients had history of unilateral nephrectomy due to nephrolithiasis many years ago and in the recent times they developed ESRD and start maintenance hemodialysis are not involved. patients with unilateral stones and those with renal stones and diabetes mellitus, hypertension, adult polycystic kidney disease or other possible cause for renal failure are also excluded from the study.

*Statistical methods:* Anderson darling test was done to test the normality of age and found that age follow normal distribution so mean and standard deviation (SD) was chosen to present the age, this considering continuous variable.

*Discrete variable:* Age groups (ordinal presentation of age as increment by 20 years) and gender were presented using number and percentage. Two sample chi square tests were used to analysis the possible association between discrete variable with nephrolithiasis and ESRD, P value where chosen to be significant when less than 0.05. All data were analyzed using SPSS 20 soft package.

#### Results

The overall proposition of nephrolithiasis related ESRD among the total number of incident ESRD cases was 4.91% (i.e, 49 of 996 patients) as seen in table 1.

Table-1: Prevalence of nephrolithiasis induced   ESRD						
Variable	Nephrolithiasis		ESRD		Total	
	No	%	No	%	10141	
	49	4.92	947	95.08	996	

Table 2 and figure 1 show that the mean age of the patients with nephrolithiasis induced ESRD was  $56.41 \pm 8.26$  years (range of 38-71 years old), 28 patients (57.14%) distributed between ages 40 to 59 years old, 19 patients (38.77%) within age 60 years old and more, while only 2patients (4.08%) seen between ages 20 to 39 years old and no patients reported below age of 20 years old. Regarding patients with ESRD from causes other than nephrolithiasis,427 patients (45.08%) distributed between ages 40 to 59 years old, 323 patients (34.10%) within age 60 years old and more, 139 patients (14.67%) seen between ages 20 to39 years old and 58 patients (6.12%) reported below age of 20 years old. P value for age is 0.006.

Table-2: Prevalence of nephrolithiasis inducedESRD according to age							
Age group	Nephrolithiasis		E	Р			
	No	%	No	%	value		
< 20	0	0	58	6.12			
20 - 39	2	4.08	139	14.67	0.006		
40 - 59	28	57.14	427	45.08	0.000		
$\geq 60$	19	38.77	323	34.10			
Mean ± SD							
Age grou	Age group 56.41 ± 8.26						
P value significant when less than 0.05							

**Fig-1:** Prevalence of nephrolithiasis induced ESRD according to age




Table 3 figure 2 show that of the 49 patients, there were 20 men (40.81%) and 29 women(59.18%) with a gender ratio of 0.73while patients with ESRD from causes other than nephrolithiasis show the reverse,607 (64.09%) patients are men and 340 (35.90%) patients are women. P value for the sex is 0.001.

Table-3: Prevalence of nephrolithiasisinduced ESRD according to gender						
Gender	Nephrolithiasis		E	Р		
	No	%	No	%	value	
Female	29	59.18	340	35.90	0.001	
Male	20	40.81	607	64.09		
P value significant when less than 0.05						

**Fig-2:** Prevalence of nephrolithiasis induced ESRD according to gender




Table 4 shows the clinical and demographic characteristics, duration of symptoms as well as duration of Hemodialysis patients underwent.

Table-4: Clinical and demographic characteristics					
Variable	Number	Percentage			
Symptoms = 49					
Renal colic	21	42.9			
Accidental discovery	8	16.3			
UTI	6	12.2			
Macroscopic hematuria	6	12.2			
Kidney failure	5	10.2			
Anuria	3	6.1			
<b>Duration of symptoms = 49</b>					
< 1 months	3	6.1			
1-6 months	3	6.1			
0.5 – 1 years	10	20.4			
1-2 years	14	28.6			
2 – 3 years	8	16.3			
3 – 4 years	5	10.2			
4 – 5 years	4	8.2			
5 – 6 years	1	2.0			
> 6 years	1	2.0			
Duration of dialysis = 49					
< 6 months	10	20.4			
6 – 12 moths	13	26.5			
12 – 18 months	8	16.3			
18 – 24 months	7	14.3			
24 – 30 months	6	12.2			
30 – 36 months	4	8.2			
>36 months	1	2.0			

# Discussion

In our study, nephrolithiasis related ESRD contributed 4.91% (49 patients out of total 996 patients) of the total series of patients who started maintenance dialysis therapy in departments of dialysis in the hospitals mentioned during a

period of 6 months. These results are agreement and non-agreement with those extracted from recent studies done in the foreign countries where they show lower and higher rates of nephrolithiasis induced ESRD table 5.

	Table-5: Reported nephrolithiasis prevalence in foreign countries							
No	Study	Country	Patients	Time	Prevalence	Time	Prevalence	Agreement
1	Paul et al [13]	USA	1391	1989	4.7%	2000	3.2%	No
2	Nowfar et al [14]	Us	181092957	1998	0.52%	2003	0.47%	No
3	Ounissi et al [8]	Indian	7128	1992	-	2006	0.63%	No
4	Scales et al [15]	Us	12110	2007	-	2010	8.8%	yes

In our study, of the 49 patients with nephrolithiasis induced ESRD 20 patients were men and 29 patients were women. This is different with phillip and franco & Stefano [16-17] showed that men are at greatest risk of developing nephrolithiasis with incidence and prevalence rates between two and four times that of women and in agreement with Stamatelou et al, Taylor et al and Pearle et al [18-20] suggested that nephrolithiasis prevalence is more common in women compared with man to have stones

Historically, kidney stones have occurred more commonly in men than in women. However, by any number of metrics, the gender gap in stone disease is closing [18, 21-22]. Administrative data from the Nationwide Inpatient Sample showed a decline in the male-to-female ratio among hospital discharges with a primary diagnosis of kidney or ureteral stone from 1.7:1 in 1997 to 1.3:1 in 2002 [22]. The change in the male-to-female ratio is thought to reflect a disproportionate increase in stone disease among women, rather than a decline among men [18]. The reasons for the observed rise in stone disease among women are not certain, but the impact of obesity, a known risk factor for kidney stones, was found to be greater in women than in men[19-20]. Also, the increased prevalence of nephrolithiasis induced ESRD in this study compared to other studies may be attributed to many factors. Irreversible renal impairment was observed essentially in patients with a delayed diagnosis, suboptimal urological and medical management, or intrinsically severe forms of stone disease.

Severe forms of nephrolithiasis, remain an underestimated cause of potentially avoidable ESRD and the need RRT. Those patients had first presentation as CKD and they were mainly having staghorn stones, so this must be kept in mind in view of the disastrous consequences that may resultfrom delayed or improper diagnosis and treatment. Other factors were mainly related to the low patients education about their symptoms and the future risks, because many patients ignored their symptoms until presentation with more advance complications. Adequate analysis of stones crystalluriatogether and/or with proper metabolic evaluation are of crucialdiagnosis value. They should never be neglected, especially in patients with the onset of nephrolithiasis childhood. in severely recurrent stones, nephrocalcinosis or incipient renal insufficiency.

*Limitations:* This study is limited by the fact that people with kidney stones were identified by their presentation to health services, meaning that our findings do not apply to those who did not seek medical care for a stone episode. Consequently we cannot comment perfectly on the association between asymptomatic kidney stones and adverse renal outcomes. We were not able to determine the composition of the kidney stones and thus cannot assess the specific risk associated with different stone types. Finally, since the dataset we used did not include genetic information, we cannot assess how many of the patients in our study had a monogenic disorder predisposing to stones.

# Conclusion

Nephrolithiasis remains the cause of potentially avoidable ESRD in too many patients despite recent major advances in the diagnosis and management of patients forming stones. These findings highlight the crucial importance of accuratestone analysis metabolic evaluation and to provide earlydiagnosis and proper therapy for a condition that may lead to ESRD through recurrent stone formation and/or crystalinfiltration. ESRD and RRT shouldbe prevented in the future in most patients with renal stone disease.

### References

- Longo D, Fauci A, Kasper D, et al. Harrisons principles of internal medicine, 18<sup>th</sup> edition, *McGraw-Hill*, 2012; 2382-2387.
- 2. Hladik GA, Collier VC, Contreras G, Hoenig M, Paparello J, Townsend RR, Watnick S. Medical

Knowledge Self-Assessment Program. *Nephrology*, 2012; 74-76.

3. Noshad H, Ahmadpoor F, Soltanpour B, Ghojazadeh M. Study of renal stones complications

in 200 patients in Tabriz, Iran. J Anal Res Clin Med, 2014; 2(4): 187-192.

- Kiddis MT, Rule AD. Nephrolithiasis and loss of kidney function. *Curr Opin Nephrol Hypertens*, 2013; 22(4):390-396.
- Eiesner BH, Eisenberg ML, Stoller ML. Relationship between body mass index and quantitative 24-hr urine chemistries in patient with nephrolithiasis. *Urology*. 2010; 75(6):1289-1293 (*PMID*:20018350).
- 6. Sakhaee K. Nephrolithiasis as a systemic disorder. *Curr Opin Nephrol Hypertens*. 2008; 17:304-309.[*PubMed*].
- 7. Robertson WG. Methods for diagnosing the risk factors of stone formation. *Arab J Urol.* 2012; 10 (3):250-257.
- 8. Ounissi M. Nephrolithiasis induced end stage renal disease, *International Journal of Nephrology and Renovascular disease*, 2010; 21-22.
- 9. Asplin JR. Evaluation of the kidney stone patient. *Semin Nephrol* 2008; 28:99. [*PMID:18359391*].
- Goldfarb DS. In the clinic. Nephrolithiasis. Ann Intern Med. 2009; 151(3):ITC2. (PMID:19652185).
- 11. Cameron MA, Sakhaee K. Uric acid nephrolithiasis. Urol Clin North Am 2007; 34:335 [PMID: 17678984].
- 12. Abboud H and Henrich WL. Stage IV Chronic Kidney Disease. *N Angl J Med* 2010; 362:56-65.
- Jungers P, Joly D, Barbey F, Choukroun G, Daudon M. ESRD caused by nephrolithiasis: prevalence, mechanisms, and prevention. *Am J Kidney Dis* 2004; 44:799-805. [*PubMed*]

- Nowfar S, Palazzi-churas K, et al. The relationship of obesity and gender prevalence changes in united states in patient nephrolithiasis. *Urology*. 2011; 78(5):1029-33.
- Scales CD Jr, Smith AC, Hanley JM, Saigal CS. (2012). Prevalence of kidney stones in the United States. *Eur Urol.* 2012; 62:160-5.
- 16. Phillip H. Nephrolithiasis. Center for continuing education (*Cleveland Clinic*). 2010.
- 17. Franco L and Stefano M. Hypercalcemia pathophysiology and treatment. *Bentham and Books.* 2009; 105.
- Stamatelou KK, Francis ME, Jones CA et al. Time trends in reported prevalence of kidney stones in the United States 1976-1994. *Kidney Int* 2003; 63:1817.
- Taylor EN, Stampfer MJ and Curhan GC. Obesity, weight gain, and the risk of kidney stones. *JAMA* 2005; 293:455.
- 20. Pearle MS, David SG, Dean GA et al. Medical management of kidney stones. *American Urological Association Guidelines*. 2014; 1-26.
- 21. Pearle MS, Calhoun EA and Curhan GC. Urologic diseases in America project. *Urolithiasis. J Urol* 2005; 173:848.
- 22. Scales CD Jr., Curtis LH, Norris RD et al. Changing gender prevalence of stone disease. J Urol 2007; 177:979.

\*All correspondences to: Dr. Ali J. Hashim Al Saedi, Department of Medicine, College of Medicine Baghdad, University of Baghdad, Medical City, Baghdad, Iraq. E-mail: dralijasm.hashim@yahoo.com / alsaedinephrology@gmail.com